Hologic launches on-demand molecular testing in Europe – Mass Device

HologicHologic (Nasdaq: HOLX) announced today that it launched its Novodiag fully automated molecular diagnostic system in Europe.

Marlborough, Massachusetts-based Hologic designed its Novodiag system for the on-demand testing of infectious diseases and antimicrobial resistance. The launch follows the company’s $795 million acquisition of Mobidiag this past summer.

According to a news release, the Novodiag system combines real-time PCR and microarray capabilities to enable multiple pathogens to be identified in a single sample, providing a simple and fast way to pinpoint patients most at risk with targeted and syndromic on-demand testing.

Novodiag’s CE-IVD test menu includes on-demand assays for gastrointestinal infections and antibiotic resistance along with a targeted assay for detecting SARS-CoV-2, the virus causing COVID-19. The company touts a strong pipeline currently in development, too.

The platform complements Hologic’s Panther system, the company says, allowing Hologic to meet customers’ growing diagnostic testing needs from small and large laboratories.

“Our acquisition of Mobidiag was aimed at strengthening our international diagnostics business. With the Hologic launch of the Novodiag system, we are delivering against this goal,” Hologic international group president Jan Verstreken said in the release. “The addition of the Novodiag system to our diagnostic molecular scalable solutions portfolio will offer more customers in Europe a wider choice of solutions that meet their needs, from single patient rapid testing to population-level screening.”

Spread the love

Leave a Reply

Your email address will not be published.